Posted by Michael Wonder on 08 Nov 2022
BioMarin announces incremental progress on biologics license application review for valoctocogene roxaparvovec AAV gene therapy for adults with severe haemophilia A program
7 November 2022 - FDA requests submission of upcoming 3 year data analysis from Phase 3 GENEr8-1 trial.
BioMarin Pharmaceutical announced today a progress update on its biologics license application for valoctocogene roxaparvovec AAV gene therapy for adults with severe haemophilia A that is currently under review by the US FDA.
